HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Karen Lundgren Selected Research

6- chloro- 9- (4- methoxy- 3,5- dimethylpyridin- 2- ylmethyl)- 9H- purin- 2- ylamine

3/2010BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy.
3/2010BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance.
8/2009Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity.
4/2009BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Karen Lundgren Research Topics

Disease

13Neoplasms (Cancer)
09/2012 - 01/2006
2Reinfection
10/2021 - 10/2019
1Infections
10/2021
1Coinfection
10/2021
1Fibrosis (Cirrhosis)
10/2021
1Hepatitis C
10/2019
1Drug Overdose
10/2019
1Gastrointestinal Neoplasms (Gastrointestinal Cancer)
02/2012
1Pancreatic Neoplasms (Pancreatic Cancer)
02/2012
1Inflammation (Inflammations)
01/2011
1Adrenocortical Carcinoma
03/2010
1Squamous Cell Carcinoma of Head and Neck
03/2010
1Hodgkin Disease (Hodgkin's Disease)
08/2009
1Retinoblastoma (Glioblastoma, Retinal)
04/2008
1Breast Neoplasms (Breast Cancer)
11/2007
1Colonic Neoplasms (Colon Cancer)
08/2006
1Residual Neoplasm
05/2006
1Stomach Neoplasms (Stomach Cancer)
01/2006

Drug/Important Bio-Agent (IBA)

5Proteins (Proteins, Gene)FDA Link
02/2012 - 04/2009
4Heat-Shock Proteins (Heat-Shock Protein)IBA
01/2011 - 04/2009
46- chloro- 9- (4- methoxy- 3,5- dimethylpyridin- 2- ylmethyl)- 9H- purin- 2- ylamineIBA
03/2010 - 04/2009
3tanespimycin (17AAG)IBA
03/2010 - 05/2006
3Biomarkers (Surrogate Marker)IBA
02/2010 - 05/2006
2Antiviral Agents (Antivirals)IBA
10/2021 - 10/2019
2Molecular Chaperones (Chaperone, Molecular)IBA
03/2010 - 08/2009
2GemcitabineFDA Link
08/2009 - 11/2007
1RNA (Ribonucleic Acid)IBA
10/2021
1Pharmaceutical PreparationsIBA
10/2021
1Dihydrotachysterol (AT 10)IBA
09/2012
1Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
02/2012
1Merozoite Surface Protein 1 (MSA1)IBA
02/2012
1macrophage stimulating proteinIBA
02/2012
1Macrocyclic LactamsIBA
03/2010
1Annexin A5IBA
08/2009
1NF-kappa B (NF-kB)IBA
08/2009
1Doxorubicin (Adriamycin)FDA LinkGeneric
08/2009
1Natural Killer Cell ReceptorsIBA
08/2009
1LigandsIBA
08/2009
1Oncogene Proteins (Oncogene Protein)IBA
04/2009
1HSP70 Heat-Shock Proteins (Heat-Shock Protein 70)IBA
04/2009
1AG-012986IBA
04/2008
1Cyclin-Dependent Kinases (cdk Proteins)IBA
03/2007
1Cytostatic AgentsIBA
03/2007
1Indicators and Reagents (Reagents)IBA
05/2006
1Insulin-Like Growth Factor Binding Protein 2IBA
05/2006
1Cyclin-Dependent Kinase 4IBA
05/2006
1AminesIBA
01/2006
1SaltsIBA
01/2006

Therapy/Procedure

4Therapeutics
10/2021 - 03/2007
2Oral Administration
04/2009 - 08/2006
1Drug Therapy (Chemotherapy)
10/2019
1Radiotherapy
03/2010